Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia
This trial is active, not recruiting.
|Treatments||cytarabine, idarubicin, allogeneic bone marrow transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation|
|Sponsor||European Organisation for Research and Treatment of Cancer - EORTC|
|Start date||December 1998|
|Trial size||60 participants|
|Trial identifier||NCT00003758, CDR0000066882, EORTC-06956|
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy consisting of cytarabine plus idarubicin in treating patients who have relapsed acute myelogenous leukemia.
|United States||No locations recruiting|
|Other Countries||No locations recruiting|
|Antwerp, Belgium||Algemeen Ziekenhuis Middelheim||no longer recruiting|
|Brugge, Belgium||A.Z. St. Jan||no longer recruiting|
|Brussels, Belgium||Institut Jules Bordet||no longer recruiting|
|Edegem, Belgium||Universitair Ziekenhuis Antwerpen||no longer recruiting|
|Zagreb, Croatia||Medical School/University of Zagreb||no longer recruiting|
|Zagreb, Croatia||University Hospital Rebro||no longer recruiting|
|Paris, France||Hopital Necker||no longer recruiting|
|Paris, France||Hotel Dieu de Paris||no longer recruiting|
|Rome, Italy||Ospedale San Eugenio||no longer recruiting|
|Rome, Italy||Policlinico A. Gemelli - Universita Cattolica del Sacro Cuore||no longer recruiting|
|'s-Hertogenbosch, Netherlands||Groot Ziekengasthuis 's-Hertogenbosch||no longer recruiting|
|Leiden, Netherlands||Leiden University Medical Center||no longer recruiting|
|Nijmegen, Netherlands||University Medical Center Nijmegen||no longer recruiting|
|Veldhoven, Netherlands||Sint Joseph Ziekenhuis||no longer recruiting|
|Porto, Portugal||Hospital Escolar San Joao||no longer recruiting|
|Ankara, Turkey||Ibn-i Sina Hospital, Ankara Univeristy||no longer recruiting|
Male or female participants from 15 years up to 60 years old.
DISEASE CHARACTERISTICS: First bone marrow relapse of primary acute myelogenous leukemia (AML), all subtypes except M3 OR First bone marrow relapse of secondary AML that occurred after other malignancies, but cured, or after alkylating agents and/or radiotherapy, or after myelodysplastic syndrome No previously untreated AML or second or subsequent relapse of AML No isolated extramedullar localization of AML Must have achieved a first complete remission No leukemias after other myeloproliferative diseases PATIENT CHARACTERISTICS: Age: 15 to 60 Performance status: WHO 0-2 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) Alkaline phosphatase no greater than 1.5 times ULN AST no greater than 1.5 times ULN Renal: Creatinine no greater than 1.5 times ULN Cardiovascular: No cardiac contraindications to anthracycline chemotherapy Ventricular ejection fraction at least 45% Other: No uncontrolled infection No concurrent severe neurological or psychiatric disease No other progressive malignant nonhematological disease PRIOR CONCURRENT THERAPY: Biologic therapy: No prior allogeneic or autologous bone marrow or peripheral stem cell transplant Chemotherapy: See Disease Characteristics Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics Surgery: Not specified
|Official title||Treatment of Relapsed Acute Myelogenous Leukemia Consisting of Intermediate Dose Cytosine Arabinoside (ARA-C) Plus Interspaced Continuous Infusion Idarubicin, Followed by Continuous Infusion of Low-Dose ARA-C, A Phase II Study by the EORTC-LCG|
|Description||OBJECTIVES: I. Assess the feasibility and efficacy of intermediate dose cytarabine plus idarubicin followed by low dose cytarabine in patients with relapsed acute myelogenous leukemia. OUTLINE: This is a multicenter study. Patients receive intermediate dose cytarabine IV over 2 hours twice a day on days 1-5, idarubicin IV over 24 hours on days 1, 3, and 5, and low dose cytarabine IV over 24 hours on days 6-15. If patients achieve complete remission by day 35, this regimen is repeated once. If patients achieve partial remission by day 35, this regimen is repeated, except with an additional day of idarubicin on day 7. If these patients then achieve complete remission by day 70, the regimen is repeated. Patients may then undergo stem cell transplantation within 6 months of achieving complete remission. Patients who have an HLA identical sibling available receive an allogeneic transplant; others receive an autologous transplant. Patients are followed monthly for 1 year, every 3 months for 3 years, then every 6 months thereafter. PROJECTED ACCRUAL: A total of 24-60 patients will be accrued for this study.|
Call for more information